Medical Director Articles

The term "article" is used to describe any bulletin article, web site article, educational handout or any other non-LCD document intended for public release that contains coverage/coding statements or medical review related billing or claims considerations.

Articles address local coverage, coding or medical review related billing and claims considerations, and may include any newly developed educational materials, coding instructions or clarification of existing medical review related billing or claims policy.

The article listing will continue to expand as additions are made.

Last Updated Jan 30 , 2024
Articles Source Posted
Billing and Coding: MolDX: LPA-Aspirin Genotype (A55279) Retirement - Effective April 16, 2024 Apr 25, 2024
Billing and Coding: MolDX: HBB Gene Tests (A55253) Retirement - Effective April 17, 2024 Apr 25, 2024
Billing and Coding: MolDX: LPA-Intron 25 Genotype (A55281) Retirement - Effective April 17, 2024 Apr 25, 2024
Billing and Coding: Cryoneurolysis Instructions (A59752) - Effective January 1, 2024 Apr 25, 2024
Billing and Coding: Benign Skin Lesion Removal (Excludes Actinic Keratosis, and Mohs) (A57161) - R3 - Effective October 1, 2019 Apr 25, 2024
Billing and Coding: Peripheral Nerve Stimulation (A55530) - R7 - Effective March 1, 2024 Apr 25, 2024
Billing and Coding: Trigger Point Injections (A57701) - R5 - Effective April 1, 2024 Apr 25, 2024
Billing and Coding: Wound and Ulcer Care (A58565) - R6 - Effective April 1, 2024 Apr 25, 2024
MolDX: Repeat Germline Testing (L38351) - R2 - Effective April 25, 2024 Apr 25, 2024
MolDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer (L38972) - R1 - Effective April 18, 2024 Apr 18, 2024
Polysomnography and Other Sleep Studies (L36861) - R4 - Effective December 01, 2019 Apr 18, 2024
Billing and Coding: MolDX: ApoE Genotype (A55094 ) - R4 - Effective April 3, 2024 Apr 11, 2024
Billing and Coding: MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing (A58720) - R17 - Effective February 29, 2024 Apr 11, 2024
Trigger Point Injections (TPI) (L34211) - R9 and Billing and Coding: Trigger Point Injections (TPI) (A57701) - R4 - Effective April 1, 2024 Apr 11, 2024
Billing and Coding: MolDX: Proteomics Testing (A59641) - R3 - Effective April 1, 2024 Apr 11, 2024
Billing and Coding: MolDX: Repeat Germline Testing (A57331) - R11 - Effective April 1, 2024 Apr 11, 2024
Additional 2024 CPT/HCPCS Local Coverage Article (LCA) Update Apr 04, 2024
Billing and Coding: Implantable Infusion Pumps for Chronic Pain (A55239) - R17 - Effective April 1, 2024 Apr 04, 2024
Self-Administered Drug Exclusion List (A53032) - R34 - Effective April 1, 2024 Apr 04, 2024
Billing and Coding: MolDX: Short Tandem Repeat (STR) Markers and Chimerism (CPT® codes 81265-81268) (A57842) - R3 - Effective April 4, 2024 Apr 04, 2024
Billing and Coding: MolDX: Molecular Diagnostic Tests (MDT) (A57526) - R18 - Effective April 01, 2024 Apr 04, 2024
Micro-Invasive Glaucoma Surgery (MIGS) Final LCD - Effective March 23, 2020 Apr 01, 2024
MolDX: Biomarkers in Cardiovascular Risk Assessment (L36358) - R10 - Effective March 21, 2024 Mar 28, 2024
MolDX: Next-Generation Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid Malignancies (L38123) - R2 - Effective March 28, 2024 Mar 28, 2024
Minimally Invasive Arthrodesis of the Sacroiliac Joint (SIJ) - Published for Review and Comments Mar 28, 2024
Open Meeting Announcement Minimally Invasive Arthrodesis of the Sacroiliac Joint (SIJ) - April 18, 2024 Mar 28, 2024
2024 CPT/HCPCS Local Coverage Article (LCA) Updates Mar 28, 2024
Billing and Coding: MolDX: Molecular Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer (A58718 ) - R3 - Effective March 12, 2024 Mar 21, 2024
Billing and Coding: MolDX: Targeted and Comprehensive Genomic Profile Next-Generation Sequencing Testing in Cancer (A55624) - R10 - Effective March 21, 2024 Mar 21, 2024
Billing and Coding: MolDX: Proteomics Testing (A59641) - R2 - Effective January 31, 2024 Mar 14, 2024